Anaptys: Vanda imsidolimab PDUFA itinakda sa Dis 12 2026 sa GPP

Ang press release ay nagsasaad na ang FDA ay nagtalaga ng target action date na December 12, 2026 para sa imsidolimab BLA sa generalized pustular psoriasis. Ito lang ang hinaharap na regulatory milestone na malinaw na may petsa sa dokumento.

Mahahalagang fact

Na-file: May 12, 2026, 08:17 PM
Kaganapan: Naitakda ang petsa ng PDUFA
Direksyon: Neutral
Kumpanya: ANABAnaptysBio
Asset: imsidolimab
Pinagmulan: SEC 8-K
Kumpiyansa: May source
Kalendaryo: Desisyon ng FDA (PDUFA) · Dis 12, 2026

Sipi mula sa source

EX-99.1 2 anab-ex99_1.htm EX-99.1 EX-99.1 Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update • Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business • Now exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda • Announced appointment of Chris Murphy as CFO • Announced appointments of Susannah Gray, former CFO of Royalty Pharma, and Owen Hughes, current CEO of XOMA Royalty, to its Board of Directors SAN DIEGO, CA — May 12, 2026 — AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today reported financial results for the first quarter ended March 31, 2026, and provided a busin

SEC 8-K